Vascular endothelial growth factor appears to have a vital role in the pathogenesis of proliferative DR, 5 whereas advanced glycation end products modify the vitreous properties. 6 The new vessels are often adherent to the posterior hyaloid face, with subsequent traction that can lead to vitreous haemorrhage (VH) and/or tractional retinal detachment. 7 The visual outcome after early vitrectomy in type 1 diabetics is well established: The Diabetic Retinopathy Vitrectomy study (DRVS) 8, 9 for severe VH examined 616 eyes with VH reducing visual acuity (VA) to 5/200 or less and had a VH for a least 1 month, with surgery carried out within 6 months of VH. They reported improved VA at both the 2-year and 4-year follow-up in type 1 diabetics compared with the deferral group. However, this benefit was not mirrored in the type 2 diabetics.
With further advances in vitrectomy techniques and instrumentation, [10] [11] [12] [13] as well as the advent of endolaser, [14] [15] [16] [17] the visual outcome of a type 1 diabetic patient improved further. 18 The literature suggests that only type 1 diabetics benefit from early vitrectomy and endolaser. We present the result of long-term visual outcomes in a predominantly type 2 diabetic population, with VH and no evidence of tractional retinal detachment affecting the macula.
Materials and methods
A retrospective review of the case notes of 88 eyes of 80 patients who had vitrectomy and endolaser within 6 months of VH for proliferative DR was carried out. All operations were carried out by a single surgeon (LB) between 2000 and 2007, with at least 2 years of follow-up (range 24-100 months, mean 44 months).
Study population
In all, 69 eyes of 62 patients were type 2 diabetics and the remaining 19 eyes of 18 patients were type 1 diabetics.
Data collected
General patient demographics such as age and gender were recorded, as well as type, duration, and classification of DR, both pre-and post-operatively. Pre-operative, post-operative, and most recent VA, laser burns before and at surgery were also compared. Any operative complications were noted.
Operative procedure
All patients underwent a 20-gauge three-port pars plana vitrectomy, removing blood and vitreous from the anterior to posterior vitreous face with a suction cutter probe.
9 Fibrovascular membranes were removed by delamination and/or segmentation, as appropriate. Green-scatter endophotocoagulation was applied to fill in areas of untreated retina. Fluid/air exchange was performed if retinal holes were found or caused during surgery, and if the patient was postured appropriately.
Results
The mean age of the 62 type 2 diabetic patients was 63.1 years, with an average duration of diabetes of 18.4 years before vitrectomy. In the type 1 population, the average age was 47.9 years with the duration of diabetes before surgery being 25.7 years. The male/female ratio was 48 : 21 in the type 2 group and 10 : 9 in the type 1 group. In the type 2 group, diabetes was controlled with insulin in 44 patients, tablets in 23 patients, and diet only in 2 patients.
Laser burns
All patients had proliferative DR with VH, and underwent surgery within 6 months, as recommended by the DRVS. The mean numbers of laser burns before surgery were 1865 and 2431 in the type 2 and type 1 population, respectively. The mean operative endolaser burns were 580 and 552 in the type 2 and type 1 populations, respectively.
VA
Mean pre-operative VA in the type 2 group was 0.64 logMAR, with one eye showing perception of light (PL), 10 eyes detecting hand movements (HMs), and seven eyes counting fingers (CFs). At the 2-week post-operative visit, the mean VA had improved to 0.46 logMAR, with 2 eyes showing PL, 2 eyes detecting HM, and 1 eye CF. At the most recent clinical appointment, the mean VA score was 0.36 logMAR, with three eyes showing PL and four eyes detecting HM ( Table 1 ). The improvement in VA at post-operative review as well as at the most recent clinical appointment was statistically significant: P ¼ 0.0002 and P ¼ 0.0008, respectively.
Mean pre-operative VA in the type 1 group was 0.47 logMAR, with one eye showing PL, one eye detecting HM, and two eyes CF. At the 2-week post-operative visit, the mean VA had improved to 0.37 logMAR, with one eye showing PL. At the most recent clinical appointment, the mean VA was 0.20 logMAR (Table 1) . Again, the improvement in VA at the post-operative review as well as at the most recent clinical appointment was statistically significant: P ¼ 0.002 and P ¼ 0.027, respectively. 
Retinopathy classification
All patients pre-operatively had active proliferative disease and some (see below) showed evidence of tractional retinal detachment (macular sparing). The final retinopathy grading of the type 2 population showed only one eye with active proliferative disease and with the other 68 eyes graded as treated (currently inactive) proliferative DR. A total of two patients had clinically significant macular oedema and one patient had ischaemic maculopathy. In the type 1 group, none of the patients was proliferating at their last clinical appointment, and one patient had clinically significant macular oedema.
Intra-operative complications
There were no intra-operative complications; however, six eyes (8.7%) of the type 2 group and three eyes (15.8%) of the type 1 group had non-macular tractional retinal detachment discovered at the time of surgery. None of these progressed to involve the macula, and at the final follow-up visit, three eyes (4.3%) in the type 2 group and no eyes in the type 1 group showed evidence of localised non-macular tractional retinal detachment. Follow-up ranged from 24 to 100 months, with no patients lost during follow-up.
Comparison with DRVS
The criteria for patients in the DRVS included vitrectomy within 6 months, VA between 5/200 to light perception. Using the same criteria, 24 eyes of 21 patients with type 2 DM and nine eyes of seven patients with type 1 DM were identified. The VA outcomes after 2 years were compared with the DRVS 2-year follow-up 7 (in which endolaser was not used) as well as with the study conducted by Chaudhry et al 18 (in which endolaser was used) ( Table 2 ).
In the type 2 DM group, the pre-operative VA score was an average of 1.6 logMAR in 5 eyes, CF in 6, HM in 12, and PL in 1. At the 2-week post-operative visit, the VA score had improved to 0.60 logMAR, with two eyes showing PL. At the most recent clinical appointment, the VA scores improved to 0.36 logMAR, with two eyes showing PL and one eye detecting HM.
In the smaller type 1 DM group, the pre-operative VA was CF in six eyes, HM in one, and PL in two. At the 2-week post-operative visit, the VA had improved to 0.63 logMAR, with two eyes detecting HM and one eye showing PL. At the most recent clinical appointment, the VA scores improved to 0.48 logMAR, with one eye showing PL.
Comparing the results directly with the DRVS, 58.3% of type 2 and 66.7% of type 1 DM patients achieved VA equal to or better than 6/12, compared with 24.5% in the DRVS. These cumulative figures for VA equal to or better than 6/60 were 83.3 and 66.7% for the type 2 and type 1 DM groups, respectively, compared with 53.8% in DRVS.
Discussion
The majority of patients with proliferative DR are treated successfully with panretinal photocoagulation. [19] [20] [21] Numerous studies including the DRVS 8, 9 have clearly demonstrated the advantage of early surgical intervention in the more severe cases in the type 1 DM population. Adjuvant endolaser has been shown to further improve long-term visual outcome. 18 There is no evidence, however, to suggest that this benefit is obtained in the type 2 DM population. The improved visual outcomes in type 1 DM population was speculatively put down to better macula function, less development of lens opacity, and lesser susceptibility to untoward events. 8 It was also suggested that the younger type 1 DM patients had greater severity of new vessels, fibrous proliferations, and vitreoretinal adhesions.
It is broadly accepted now that leaving a VH in situ while retinopathy may continue unobserved is unacceptable, and that early vitrectomy in a non-clearing VH is useful for not only clearing the visual media but also allows retinal observation and may stabilise the retinopathy.
Our study shows that type 2 DM patients can obtain sustained improvement in VA and stabilisation of their proliferative retinopathy after early vitrectomy and endolaser that is comparable to the type 1 population, a finding that was not mirrored in the DRVS. The reason for this difference is likely to be mutifactorial; earlier intervention, better instrumentation, adjuvant operative endolaser, and panretinal photocoagulation before VH are all likely to have a role in better long-term outcomes with regard to VA, as well as retinopathy classification, compared with the DRVS population. It would be interesting to observe whether this improvement is more pronounced with small-gauge vitrectomy, and whether the visual recovery is more rapid compared with the 20-gauge vitrectomy in our population.
Clearly, each patient's particular situation and disease state must be carefully considered; however, there is growing evidence that early vitrectomy for VH, in the absence of tractional retinal detachment affecting the macula, has a beneficial effect of long-term visual outcomes in proliferative retinopathy.
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1.
Which of the following is considered the most important factor in the pathophysiology of proliferative diabetic retinopathy? 
